SGO Winter Meeting Submission Guidelines
Submission Type
- Abstract: Innovative science covering a range of topics that are relevant to gynecologic oncology
Submission Eligibility
- An abstract may not be submitted for consideration to both Annual and Winter Meeting — only one.
- Submission of an abstract constitutes a commitment by the author to register for and attend the Winter Meeting to present, if the abstract is accepted. The presenting author(s) must be registered by December 18, 2026.
- Submitting authors must:
- Be a current student, resident, or fellow.
- Have substantially contributed to the work.
- Disclose if the abstract has been previously presented at a national or international meeting. If so, it is not eligible for submission (prior presentation at regional meetings is allowed).
- Disclose if any data in this abstract has been previously presented or published (ex: abstract submitted is an update on previously presented research).
- If part of the work was previously published, the author must declare that the work being submitted contains substantial updates than what was previously presented. This does not make the abstract ineligible for submission.
- Include the NCT# for reports on clinical trials, if applicable.
- Identify the Presenting Author, who completes the disclosure form before the submission deadline and agrees to attend the Winter Meeting and present the abstract, if accepted.
- SGO does not cover registration fees, travel, or related expenses.
- Submission does not require fees, sponsorship, or SGO membership.
- SGO may decline or withdraw abstracts at its discretion.
- Submissions must present new, unpublished, and previously unpresented science for the SGO 2027 Winter Meeting (January 21–23, 2027). Previously presented or ongoing work may be considered only if it includes significant new findings and is approved by the SGO Winter Meeting Chairs.
Submission Requirements
- SGO reserves the right to use an editor to check for errors and make minor updates.
- Each abstract submission must clearly identify the following:
- Title: Describe the nature of the content but does not include author or affiliation identifying terms. Use sentence case and capitalize only the first word and proper nouns.
- Example: Combination of BVAC-C and durvalumab in recurrent or metastatic cervical cancer: A phase II study
- Objectives: An introductory sentence indicating the purpose of the study
- Methods: A brief description of pertinent experimental procedures, including statistics
- Results: A summary of the new, unpublished data
- Conclusions: A statement of the conclusions
- Character Limit: 2,500 characters, including spaces; this does not include abstract title, author string, nor a single allotted table or graph.
- Institution Names and Location: Abstract text must be anonymous for grading purposes. Do not reference institution names or locations in the body of your abstract.
- No Use of Brand Names and Trade Names in Submissions: Brand names of pharmaceuticals and trade names of medical devices cannot be used in the title or body of the abstract.
- Table/Graph: Each abstract submission is limited to one (1) table or graph. Do not enter charts, graphs, bullet points, indentations, or references in the abstract text.
- Language Format and Grammar: Text must be in English. Review your abstract for grammar and spelling errors prior to submitting.
Submitters are encouraged to review the full SGO 2027 Winter Meeting Submission Guidelines.
Review Process
The Winter Meeting Abstract Review Committee will conduct a blinded review of all submissions, prioritizing clinical abstracts. Awards will be given for the best oral presentation and the best scientific poster, based on scientific content, originality, potential impact, and quality of presentation.
Start your submission
Key Dates
- September 1, 2026 – Abstract portal opens
- October 5, 2026 – Abstract portal closes
- October 9-16, 2026 – Review period
- Mid-November 2026 – Notifications out
Questions? Contact the SGO Education Department.
